Sharon Begley March 8, 2016 The U.S. Patent and Trademark Office will begin proceeding that will determine the recipients of patents covering the use of CRISPR-Cas9 genome-editing technology. George Church (HMS) is mentioned. Read the full article
The Economic Forces That Drive Prescription Drug Prices October 30, 2025 Luca Maini on what new U.S. policies could mean for patients and health systems
HMS Announces Blavatnik Institute Early Career Investigator Awards November 6, 2025 10 projects receive basic and translational research funding
CTE Is Caused by More Than Head Trauma, New Study Suggests October 30, 2025 Research reveals Alzheimer’s disease-like DNA damage, hints at immune involvement
